@article{APS8989,
author = {Hai-Ying Wang and Shu-Jun Zeng and Peng-Xin Qiu},
title = {Development of muscarinic m3 and m4 receptor antibodies with pharmacological activities},
journal = {Acta Pharmacologica Sinica},
volume = {19},
number = {6},
year = {2016},
keywords = {},
abstract = {AIM: To investigate the feasibility of developing subtype-selective anti-receptor antibodies with pharmacological activities for the study of subtypes of receptors. METHODS: New Zealand white rabbits were immunized with synthesized subtype-selective peptide segments of m3 and m4 receptors to develop antibodies. The effects of the antibodies on ligand-binding to muscarinic receptors were studied by competitive radioligand assay. The effects of the prepared antibodies on the contraction or relaxation activity of ACh in isolated rat ilea and aortic rings were studied.
RESULTS: Antibodies against synthesized m3 and m4 receptor subtype-selective peptides were successfully prepared. Both antibodies inhibited [3H]QNB binding to muscarinic receptors with different maximal inhibitions which may be the proportions of m3 or m4 subtypes among the total muscarinic receptors in the tissues. The maximal inhibitory rates in rat cerebral cortex, myocardium, and salivary glands were 12.1% +/- 2.1%, 15.7% +/- 1.1%, and 63.6% +/- 2.8% for m3 antibodies, whereas 28% +/- 6%, 19.3% +/- 2.6%, and 1.6% +/- 1.4% for m4 antibodies respectively. The m3 antibodies inhibited the contraction activity of ACh in isolated rat ilea and the relaxation activity of ACh in isolated rat aortic rings.
CONCLUSION: It is feasible to develop subtype-selective anti-receptor antibodies as new tools in the study of the functions of m3 and m4 subtypes of muscarinic receptors.},
issn = {1745-7254}, url = {http://www.chinaphar.com/article/view/8989}
}